 ft 19 92 technolog gambl gut reaction pharmaceut industri make startl advanc drug discoveri paul abraham begin seri progress ulcer treatment  lead gastro enterologist gather san francisco week discuss signific singl bacterium outcom debat shape drug industri valuabl market peptic ulcer medic worth dollar 7bn pound 3 9bn year bacterium question helicobact pylori hp specialist bacterium play vital role recurr stomach duoden ulcer 80 cent patient ulcer heal subsequ relaps specialist argu erad bacterium stomach risk recurr elimin impact success hp cure ulcer drug market strike half prescript lead class ulcer drug h2 antagonist mainten therapi prevent relaps sale lead h2 antagonist glaxo zantac smithklin beecham tagamet total dollar 4bn year accept method erad hp found profound chang long term manag peptic ulcer diseas argu ander vedin presid astra hassl gastro intestin research divis astra swedish pharmaceut group sell altern therapi erad hp elimin mainten market h2 antagonist lead signific save healthcar cost maintain give relief 15 cent popul affect peptic ulcer time live peptic ulcer caus imbal aggress qualiti stomach acid break food defens mechan stomach line hydrochlor acid start digest meat stomach line pain potenti danger condit reason imbal unknown diet alcohol consumpt smoke effect stress factor doctor 10 20 cent patient take steroid anti inflammatori drug treat arthriti develop ulcer month specialist increas focus attent hp found 90 cent patient duoden ulcer 70 80 cent peptic ulcer problem establish causal link hp ulcer john wood director medic affair group research glaxo uk pharmaceut compani market world sell drug h2 antagonist zantac larg proport popul infect bacterium fail develop ulcer believ hp factor  present main method deal peptic ulcer histor widespread treatment anti acid milk magnesia counteract acid stomach event sever complic patient requir surgeri expens potenti danger procedur earli 1980s tradit method larg abandon develop class drug h2 antagonist work reduc amount acid produc stomach line cell respons secret acid natur trigger histamin releas stomach h2 antagonist act block action histamin acid secret cell ulcer heal h2 antagonist prevent relaps studi shown 7 cent patient take zantac recurr duoden ulcer year compar 49 cent stop take treatment glaxo reckon 80 cent patient heal ulcer relaps mainten therapi recent class treatment proton pump inhibitor develop sell version losec market astra sweden drug work control final step acid secret block action tini acid pump stomach wall reduc acid level stomach creat suitabl environ heal heal patient prescrib h2 antagonist prevent recurr year continu life expens process attent gastro enterologist turn erad hp bacterium eventu end long term mainten therapi specialist unsur relationship hp recurr ulcer vedin astra appear biochem similar hp organ protein gastric line lead damag effect emerg occur present drug requir elimin hp treatment involv take 25 tablet time day week patient understand tendenc follow regim proper problem bacteri resist acid resist antibiot involv treatment drug administ hospit patient frequent relaps race develop easili administ treatment replac exist tripl therapi prescrib general practition takeda japan astra separ conduct trial proton pump inhibitor antibiot amoxycillin astra believ reduct acid level achiev inhibitor amoxycillin work effect studi present american gastro enterolog associ annual confer week show astra answer hp problem studi demonstr losec amoxycillin erad hp 80 cent duoden ulcer patient remain ulcer free 12 month treatment specialist experi work effect dosag preliminari work gastric ulcer rarer duoden glaxo develop zantac base treatment hp call ranitidin bismuth citrat coat ulcer protect injuri astra admit mainten therapi hp therapi work patient h2 antagonist patient ulcer form steroid anti inflammatori drug increas prefer doctor proton pump inhibitor initi treatment ulcer hit sale h2 antagonist losec won 45 cent acid inhibitor market sweden 24 cent germani uk initi limit approv drug account 13 cent 8 cent market impact effect cure hp acceler trend h2 antagonist john calam senior lectur gastro enterolog hammersmith hospit london reckon year general practition chang prescrib habit natur conservat general practition slow chang vedin estim year market alter fundament hp therapi cure diseas cure mainten market exist seri continu month mind drug  top 10 pharmaceut 1991  rank drug indic compani sale growth dollar  1 zantac ulcer glaxo 3 023 10 5 2 vasotec hypertens chf merck 1 745 14 1 3 capoten hypertens chf bms 1 580 7 5 4 voltaren arthriti geigi 1 185 5 1 5 tenormin hypertens ici 1 180 1 7 6 adalat angina hypertens bayer 1 120 12 6 7 tagamet ulcer sb 1 097 2 2 8 mevacor hyperlipidaemia merck 1 090 43 4 9 naprosyn arthriti syntex 954 10 3 10 ceclor infect lilli 935 11 3  18 losec ulcer astra 775 121 4 23 pepcid ulcer merck 595 19 0  sourc ub phillip drew  